Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML)

ABSTRACT: Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML)

PROVIDER: PRJNA522070 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Integrated high-throughput screen to identify novel treatment leads for pediatric acute myeloid leukemia (AML)

Project description:AML cell lines that underwent high throughput drug screening had baseline RNA sequencing done for the purpose of gene expression studies

2019-04-16 | GSE126489 | GEO

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Pediatric AML is an aggressive hematological malignancy associated with distinctive genomic features. We employed RNA-seq to study fusion genes and clinically relevant gene expression patterns in pediatric AML patients.

2023-05-02 | GSE222814 | GEO

A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.

Project description:Improvement in survival has been achieved for children and adolescents with AML but is largely attributed to enhanced supportive care as opposed to the development of better treatment regimens. High risk subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high intensity chemotherapy in combination with hematopoietic stem cell transplant. Here we combine high-throughput screening, intracellular accumulation assays, and in vivo efficacy studies to identify therapeutic strategies for pediatric AML. We report therapeutics not currently used to treat AML, gemcitabine and cabazitaxel, have broad anti-leukemic activity across subtypes and are more effective relative to the AML standard of care, cytarabine, both in vitro and in vivo. JAK inhibitors are selective for acute megakaryoblastic leukemia and significantly prolong survival in multiple preclinical models. Our approach provides advances in the development of treatment strategies for pediatric AML.

| S-EPMC6522510 | biostudies-literature

An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.

Project description:Using a mouse model of ependymoma-a chemoresistant brain tumor-we combined multicell high-throughput screening (HTS), kinome-wide binding assays, and in vivo efficacy studies, to identify potential treatments with predicted toxicity against neural stem cells (NSC). We identified kinases within the insulin signaling pathway and centrosome cycle as regulators of ependymoma cell proliferation, and their corresponding inhibitors as potential therapies. FDA approved drugs not currently used to treat ependymoma were also identified that posses selective toxicity against ependymoma cells relative to normal NSCs both in vitro and in vivo, e.g., 5-fluorouracil. Our comprehensive approach advances understanding of the biology and treatment of ependymoma including the discovery of several treatment leads for immediate clinical translation.

| S-EPMC3172881 | biostudies-literature

Comprehensive genetic analysis to identify causative mutations of diseases in the field of pediatric surgery

Project description:Primary outcome(s): Identification of causative mutations suggesting possible involvement in the development of each pediatric surgical disease

| 2653767 | ecrin-mdr-crc

ChIPseq for pediatric AML patients

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to explore ChIPseq results for pediatric AML patients.

2022-07-20 | GSE188605 | GEO

Expression data from pediatric AML patients

Project description:Pediatric acute myeloid leukemia (AML) is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. Detecting these aberrations however still lead to failures or false negative results. Therefore, we focused on the potential of gene expression profiles (GEP) to classify pediatric AML. Gene expression microarray data of 237 children with AML were generated and cases were split into a discovery cohort (n=157) and an independent validation cohort (n=80). Next, a double-loop cross validation approach was used to generate a subtype-predictive GEP in the discovery cohort which was then tested for its true predictive value in the independent validation cohort. 237 bone marrow and peripheral blood samples were collected at diagnosis and frozen. They were later thawed and hybridized to Affymetrix U133 Plus 2.0 arrays.

2010-10-21 | E-GEOD-17855 | biostudies-arrayexpress

pediatric AML and normal bone marrow

Project description:This series represents leukemic samples obtained from pediatric AML patients at diagnosis and control normal bone marrow samples. Keywords: other

2005-01-28 | GSE2191 | GEO

Gene expression profile of pediatric AML

Project description:Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group. RNA samples obtained at the time of diagnosis were analyzed using GeneChip Human Genome U133 plus 2.0 array (Affymetrix).

2013-04-01 | E-GEOD-35784 | biostudies-arrayexpress

Gene expression profile of pediatric AML

Project description:Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group.

2013-04-01 | GSE35784 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data